Clinical Study
Preoperative Comorbidity Correlates Inversely with Survival after Intestinal and Multivisceral Transplantation in Adults
Table 4
Peri- and postoperative data.
| Variables | Results |
| Induction agents (%) | | Corticosteroids | 13.90% | Daclizumab (Zenapax) | 16.66% | Alemtuzumab (Campath) | 69.44% | Number of rejection episodes (mean ± SD) | 1.22 ± 1.34 | Severity of rejection episodes per patient (mean ± SD) | | Mild | 1.419 ± 0.662 | Moderate | 0.391 ± 0.718 | Severe | 0.318 ± 0.547 | Rejection-free period (days) (mean ± SD) | 357.63 ± 21.54 | Posttransplant hospital stay (days) (mean ± SD) | 60.69 ± 45.57 |
|
|